Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 oxodotreotide - Jiangsu HengRui Medicine

Drug Profile

Lutetium-177 oxodotreotide - Jiangsu HengRui Medicine

Alternative Names: Lutetium (177Lu) Oxodotreotide Injection - Jiangsu HengRui Medicine

Latest Information Update: 24 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Neuroendocrine tumours

Most Recent Events

  • 06 Jul 2023 Phase-III clinical trials in Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in China (Parenteral) (NCT05884255)
  • 01 Jun 2023 Jiangsu HengRui Medicine plans a phase III trial for Neuroendocrine tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) (Parenteral) in June 2023 (NCT05884255)
  • 01 Jun 2023 Preclinical trials in Neuroendocrine tumours in China (Parenteral) prior to June 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top